🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 44 Bristol 18 Manchester 17 Oxford 15 Birmingham 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72 Clear sponsor filter
Site city
London44 Bristol18 Manchester17 Oxford15 Birmingham14
All 106 cities
Target enrolment
to
44 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336Diabetes Mellitus, Type 2
Eli Lilly and Company
Phase 3
170
Hull, Liverpool, London
2026-09
Not yet open
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
Eli Lilly and Company
Phase 2
606
Cheadle, Ely, Hounslow, London, Penzance, West Kirby
2026-08
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Eli Lilly and Company
Phase 1
460
London, Nottingham, Plymouth, Southampton
2026-04-17
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006Alopecia Areata
Eli Lilly and Company
Phase 2
60
London, Salford
2026-04-14
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283Opioid Use Disorder
Eli Lilly and Company
Phase 2
465
Chertsey, Doncaster, Eastbourne, Glasgow, London, Manchester, Milton Keynes, Southampton
2026-02-13
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
Eli Lilly and Company
Phase 3
1,000
Edinburgh, Exeter, Glasgow, London, Nottingham, Oxford, Penzance, Rotherham
2026-02-09
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
Eli Lilly and Company
Phase 3
900
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York
2026-02-09
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
800
Edinburgh, Huddersfield, London, Manchester, Plymouth, Worcester
2025-12-22
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Huddersfield, London, Manchester, Sheffield
2025-12-12
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
Eli Lilly and Company
Phase 3
1,205
London, Plymouth, Stoke-on-Trent, Swansea, West End
2025-10-31
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,630
Bath, Leeds, London, Manchester, Torquay
2025-10-22
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Blackpool, Doncaster, Eastbourne, Glasgow, Hayle, Hounslow, London, Newquay
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Blackpool, Chester, Eastbourne, Edinburgh, Glasgow, London, Manchester, Southampton
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
Phase 3
4,500
Aberdeen, Clifton, Enfield, Glasgow, Ipswich, Liverpool, London, Newcastle upon Tyne
2025-10-15
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013Immune Thrombocytopenia (ITP)
Eli Lilly and Company
Phase 1/2
68
Bristol, Leeds, Leicester, London
2025-07-30
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
Eli Lilly and Company
Phase 3
350
Bristol, Dundee, Exeter, London
2025-06-26
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
700
Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay
2025-03-27
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Bath, Birmingham, Blackpool, Edinburgh, London, Manchester, Motherwell, Plymouth
2024-10-24
Recruiting
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590Alzheimer Disease
Eli Lilly and Company
Phase 1
48
London, Sheffield, Southampton
2024-08-15
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
London, Manchester
2024-07-01
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
Eli Lilly and Company
Phase 3
300
Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield
2024-06-03
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eli Lilly and Company
Phase 3
510
Bristol, Chelsea, Great Yarmouth, London, Newcastle upon Tyne, Stockport
2024-04-29
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
Eli Lilly and Company
Phase 3
90
Edinburgh, Headington, London, Manchester, Sheffield, Whitechapel
2024-03-13
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Eli Lilly and Company
Phase 3
17,300
Blackpool, Bristol, Cheadle, Enfield, Glasgow, Hull, London, Newcastle upon Tyne
2024-03-05
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,175
Bristol, Winchester, London, Guildford, Birmingham, Plymouth
2023-02-28
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,500
Bath, Birmingham, Bristol, Chertsey, Crowborough, Guildford, London, Nottinghamshire
2022-10-10
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Colchester, East Kilbride, Glasgow, Edinburgh, Liverpool, London, Manchester, Northwood, Plymouth
2022-10-04
Recruiting
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705Breast Cancer
Eli Lilly and Company
Phase 1
260
London, Sutton
2022-05-11
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
Eli Lilly and Company
Phase 3
925
Blackburn, Colchester, London
2022-04-14
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
152
London, Nottingham, Wolverhampton
2021-12-20
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Eli Lilly and Company
Phase 3
150
London, Oxford, Sheffield
2021-05-26
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
Eli Lilly and Company
Phase 3
996
Cambridge, London, Cardiff
2020-06-22
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511Alzheimer Disease
Eli Lilly and Company
Phase 3
1,736
Motherwell, London, Guildford, Birmingham
2020-06-19
Active, closed
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT04088396Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company
Phase 3
58
Bristol, Liverpool, London, Oxford, Sheffield
2020-02-12
Recruiting
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994Neoplasms, Child, Adolescent
Eli Lilly and Company
Phase 2
105
London, Manchester
2020-01-22
Active, closed
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
NCT04088409Uveitis
Eli Lilly and Company
Phase 3
30
Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield
2019-10-16
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
Eli Lilly and Company
Phase 1/2
36
London
2019-06-13
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
Eli Lilly and Company
Phase 3
190
Bristol, Liverpool, London, Oxford, Sheffield
2019-04-05
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
Eli Lilly and Company
Phase 3
1,058
Bury, London, Oxford
2018-07-18
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
Eli Lilly and Company
Phase 3
5,637
Truro, Chelmsford, London, Northwood, Blackpool, Preston, Boston, Central Middlesbrough
2017-07-12
Active, closed
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Eli Lilly and Company
Phase 1/2
857
London
2017-05-02
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
Eli Lilly and Company
Phase 2
309
London, Manchester, Acton, Bebbington, Sutton
2016-05-19
Active, closed
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448Metastatic Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3
545
London, Chelsea, Nottingham
2015-05-06
Rows per page Showing 1–44 of 44
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.